PDF(Pubmed)
Abstract：
Abdominal aortic aneurysm (AAA) is a significant source of mortality worldwide and carries a mortality of greater than 80% after rupture. Despite extensive efforts to develop pharmacological treatments, there is currently no effective agent to prevent aneurysm growth and rupture. Current treatment paradigms only rely on the identification and surveillance of small aneurysms, prior to ultimate open surgical or endovascular repair. Recently, regenerative therapies have emerged as promising avenues to address the degenerative changes observed in AAA. This review briefly outlines current clinical management principles, characteristics, and pharmaceutical targets of AAA. Subsequently, a thorough discussion of regenerative approaches is provided. These include cellular approaches (vascular smooth muscle cells, endothelial cells, and mesenchymal stem cells) as well as the delivery of therapeutic molecules, gene therapies, and regenerative biomaterials. Lastly, additional barriers and considerations for clinical translation are provided. In conclusion, regenerative approaches hold significant promise for in situ reversal of tissue damages in AAA, necessitating sustained research and innovation to achieve successful and translatable therapies in a new era in AAA management.
摘要：
腹主动脉瘤(AAA)是世界范围内死亡率的重要来源,并且在破裂后具有大于80%的死亡率。尽管在开发药物治疗方面做出了广泛的努力，目前没有有效的药物来防止动脉瘤的生长和破裂。目前的治疗模式仅依赖于小动脉瘤的识别和监测，在最终开放手术或血管内修复之前。最近,再生疗法已成为解决AAA中观察到的退行性变化的有希望的途径。这篇综述简要概述了当前的临床管理原则，特点,和AAA的药物目标。随后，对再生方法进行了深入的讨论。这些方法包括细胞方法（血管平滑肌细胞，内皮细胞，和间充质干细胞）以及治疗分子的递送，基因疗法,和再生生物材料。最后,提供了临床翻译的其他障碍和注意事项。总之,再生方法对AAA组织损伤的原位逆转具有重要的前景，需要持续的研究和创新，以在AAA管理的新时代实现成功和可翻译的疗法。
